Article
Evolutionary trajectories of small cell lung cancer under therapy.
Nature - 1 Mar 2024
George Julie, Maas Lukas, Abedpour Nima, Cartolano Maria, Kaiser Laura, Fischer Rieke N, Scheel Andreas H, Weber Jan-Philipp, Hellmich Martin, Bosco Graziella, Volz Caroline, Mueller Christian, Dahmen Ilona, John Felix, Alves Cleidson Padua, Werr Lisa, Panse Jens Peter, Kirschner Martin, Engel-Riedel Walburga, Jürgens Jessica, Stoelben Erich, Brockmann Michael, Grau Stefan, Sebastian Martin, Stratmann Jan A, Kern Jens, Hummel Horst-Dieter, Hegedüs Balazs, Schuler Martin, Plönes Till, Aigner Clemens, Elter Thomas, Toepelt Karin, Ko Yon-Dschun, Kurz Sylke, Grohé Christian, Serke Monika, Höpker Katja, Hagmeyer Lars, Doerr Fabian, Hekmath Khosro, Strapatsas Judith, Kambartel Karl-Otto, Chakupurakal Geothy, Busch Annette, Bauernfeind Franz-Georg, Griesinger Frank, Luers Anne, Dirks Wiebke, Wiewrodt Rainer, Luecke Andrea, Rodermann Ernst, Diel Andreas, Hagen Volker, Severin Kai, Ullrich Roland T, Reinhardt Hans Christian, Quaas Alexander, Bogus Magdalena, Courts Cornelius, Nürnberg Peter, Becker Kerstin, Achter Viktor, Büttner Reinhard, Wolf Jürgen, Peifer Martin, Thomas Roman K
Abstract excerpt
The evolutionary processes that underlie the marked sensitivity of small cell lung cancer (SCLC) to chemotherapy and rapid relapse are unknown1-3. Here we determined tumour phylogenies at diagnosis and throughout chemotherapy and immunotherapy by multiregion sequencing of 160 tumours from 65 patients. Treatment-naive SCLC exhibited clonal homogeneity at distinct tumour sites, whereas first-line platinum-based...
Read the complete abstract on PubMed